Management's efforts to optimize commercial performance are evident in Gvoke’s and ... Xeris is zeroing in on the U.S. market ...

New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...

Lina Polimeni, chief corporate brand officer at Lilly, notes that public perception of the company has historically been ...

After seven months of living and working onboard the International Space Station (ISS), astronauts of NASA's eighth ...

New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...

Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of ...

Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to ...

A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...

The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

Lots of money is pouring into two critical races for Washington's legislature this year — and some big name companies are ...

The company is suing some online vendors and medical spas for selling copycats of a weight loss and diabetes drug.

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...